Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

Related news

HYPRHyperfine2026-08-20 12:15 EST

Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

HYPRHyperfine2026-07-30 12:15 EST

Hyperfine Announces the Release of Multiple Peer-Reviewed Publications, Expanding Clinical Evidence for the Swoop® System Across a Growing Number of Sites of Care

PLSEPulse Biosciences2026-09-15 11:00 EST

Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules

PLSEPulse Biosciences2026-07-29 11:00 EST

Pulse Biosciences Surpasses Enrollment Midpoint in NANOPULSE-AF IDE Pivotal Study

FEMYFEMASYS2026-08-19 13:00 EST

Femasys Announces FDA Approval of Modular PMA Submission Approach for FemBloc®

View all latest news

Hyperfine

Portable Brain MRI Company Hyperfine develops the Swoop portable magnetic resonance brain-imaging system for use at the patient’s bedside and in settings without conventional MRI infrastructure. Low-Field Imaging Platform Swoop uses low-field magnetic resonance and can be moved through hospitals, reducing the logistical burden of...